Table 7.
| Drug class | Agents (current phase in the trial) |
|---|---|
| Anthracyclines | Liposomal doxorubicin (approved) |
| Antimetabolites | Pemetrexed (phase III) |
| Antimicrotubule agents (new formulation) | Nanoparticle albumin-bound (nab)–paclitaxel (approved) |
| EndoTAG-1 (phase II) | |
| Paclitaxel poliglumex (phase II) | |
| Antimicrotubule agents (novel taxane) | Larotaxel (phase II) |
| Tesetaxel (phase II) | |
| Cabazitaxel (phase II) | |
| Antimicrotubule agents (novel non-taxane) | Vinflunine (phase III) |
| Indibulin (phase I/II) | |
| Platinum analogues | Satraplatin (phase II) |
| Topoisomerase inhibitor | NKTR-102 (phase III) |